Trial growth has dramatically outpaced site capacity since 2015, at the same time the number of new investigators participating in clinical trials has decreased by 48%. Those are just two reasons sponsors miss 80% of critical clinical trial milestones, and for smaller biopharma sponsors one missed milestone alone can create significant issues for a study and the company itself.

Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles.

Learn more about these hurdles and how you can overcome them.